Yutaka Kawakami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yutaka Kawakami has a total of 495 co-authors. Here are the top co-authors by number of shared publications:
- Tomonori Yaguchi
Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine , Kyoto 606-8501
17 shared publications Tomonobu Fujita
Institute for Advanced Medical Research Division of Cellular Signaling Keio University School of Medicine Tokyo Japan
14 shared publicationsTomonori Yaguchi
Division of Cellular Signaling, Institute for Advanced Medical Research, School of Medicine Keio University Tokyo Japan
14 shared publicationsShigeki Ohta
Division of Cellular Signaling, Institute for Advanced Medical Research Keio University School of Medicine Tokyo Japan
10 shared publications- Hideyuki Saya
Translational Research Headquarters Center for Translational Research, Fujita Health University, Toyoake
9 shared publications - Yumi Matsuzaki
Department of Life Science, Faculty of Medicine, Shimane University, Izumo, Japan
9 shared publications
Latest Publications
- Open Access
- 24 May 2026
- Published by Wiley in Cancer Science
- Vol. 117 (8) , 2152-2165
Tumor‐Derived Extracellular Vesicles in Plasma for Predicting Anti‐ PD ‐1 Antibody Efficacy in Non‐Small Cell Lung Cancer
Liquid biopsy is a promising biomarker for cancer detection and prediction of therapy responses. In this study, we developed new antibody‐based sandwich assays to measure three extracellular vesicle (EV) subsets that express cell surface vimentin (CSV) and co‐express epithelial cell adhesion molecule (EpCAM) or PD‐L1 in plasma. Fifty‐seven non‐small cell lung cancer (NSCLC) patients who underwent complete resection and 89 stage IV NSCLC patients who received anti‐PD‐1 antibody were enrolled. Correlations between the plasma EV subsets at baseline and various clinicopathological factors were evaluated. Plasma EpCAM/CSV‐EV levels were significantly higher in stage I NSCLC patients compared to healthy donors, suggesting this may be a valuable biomarker for detecting early‐stage NSCLC. High plasma CSV/CSV‐EV levels at baseline were significantly correlated with a poor prognosis after treatment, both in the surgery cohort and the anti‐PD‐1 antibody cohort, which suggests that this may be useful for predicting the post‐treatment prognosis in NSCLC patients. High plasma CSV/PD‐L1‐EV levels at baseline were significantly correlated with poor postoperative prognosis. However, high plasma CSV/PD‐L1‐EV levels at baseline were significantly correlated with a favorable clinical response and prognosis following anti‐PD‐1 antibody treatment in stage IV NSCLC. Therefore, plasma CSV‐related EV subsets at baseline may be attractive biomarkers for early cancer detection (EpCAM/CSV), prediction of postoperative prognosis (CSV/CSV), and prediction of clinical responses and prognosis after anti‐PD‐1 antibody therapy (CSV/PD‐L1). These EV subsets can be easily measured repetitively at appropriate timing. These novel liquid biopsies may be additional and complementary diagnostic biomarkers for NSCLC patients.
- 24 May 2026
- Published by Wiley in Cancer Science
- Vol. 117 (8) , 2152-2165
Open AccessTumor‐Derived Extracellular Vesicles in Plasma for Predicting Anti‐ PD ‐1 Antibody Efficacy in Non‐Small Cell Lung Cancer
Liquid biopsy is a promising biomarker for cancer detection and prediction of therapy responses. In this study, we developed new antibody‐based sandwich assays to measure three extracellular vesicle (EV) subsets that express cell surface vimentin (CSV) and co‐express epithelial cell adhesion molecule (EpCAM) or PD‐L1 in plasma. Fifty‐seven non‐small cell lung cancer (NSCLC) patients who underwent complete resection and 89 stage IV NSCLC patients who received anti‐PD‐1 antibody were enrolled. Correlations between the plasma EV subsets at baseline and various clinicopathological factors were evaluated. Plasma EpCAM/CSV‐EV levels were significantly higher in stage I NSCLC patients compared to healthy donors, suggesting this may be a valuable biomarker for detecting early‐stage NSCLC. High plasma CSV/CSV‐EV levels at baseline were significantly correlated with a poor prognosis after treatment, both in the surgery cohort and the anti‐PD‐1 antibody cohort, which suggests that this may be useful for predicting the post‐treatment prognosis in NSCLC patients. High plasma CSV/PD‐L1‐EV levels at baseline were significantly correlated with poor postoperative prognosis. However, high plasma CSV/PD‐L1‐EV levels at baseline were significantly correlated with a favorable clinical response and prognosis following anti‐PD‐1 antibody treatment in stage IV NSCLC. Therefore, plasma CSV‐related EV subsets at baseline may be attractive biomarkers for early cancer detection (EpCAM/CSV), prediction of postoperative prognosis (CSV/CSV), and prediction of clinical responses and prognosis after anti‐PD‐1 antibody therapy (CSV/PD‐L1). These EV subsets can be easily measured repetitively at appropriate timing. These novel liquid biopsies may be additional and complementary diagnostic biomarkers for NSCLC patients.
- 20 July 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (21) , 2578-2587
Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis
PURPOSE: The humanized antivascular endothelial growth factor (VEGF) antibody bevacizumab (Bev) is efficacious for the treatment of NF2-related schwannomatosis (NF2), previously known as neurofibromatosis type 2. This study evaluated the safety and efficacy of a VEGF receptor (VEGFR) vaccine containing VEGFR1 and VEGFR2 peptides in patients with NF2 with progressive schwannomas (jRCTs031180184). MATERIALS AND METHODS: VEGFR1 and VEGFR2 peptides were injected subcutaneously into infra-axillary and inguinal regions, once a week for 4 weeks and then once a month for 4 months. The primary end point was safety. Secondary end points included tolerability, hearing response, imaging response, and immunologic response. RESULTS: Sixteen patients with NF2 with progressive schwannomas completed treatment and were assessed. No severe vaccine-related adverse events occurred. Among the 13 patients with assessable hearing, word recognition score improved in five patients at 6 months and two at 12 months. Progression of average hearing level of pure tone was 0.168 dB/mo during the year of treatment period, whereas long-term progression was 0.364 dB/mo. Among all 16 patients, a partial response was observed in more than one schwannoma in four (including one in which Bev had not been effective), minor response in 5, and stable disease in 4. Both VEGFR1-specific and VEGFR2-specific cytotoxic T lymphocytes (CTLs) were induced in 11 patients. Two years after vaccination, a radiologic response was achieved in nine of 20 assessable schwannomas. CONCLUSION: This study demonstrated the safety and preliminary efficacy of VEGFR peptide vaccination in patients with NF2. Memory-induced CTLs after VEGFR vaccination may persistently suppress tumor progression.
- 20 July 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (21) , 2578-2587
Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis
PURPOSE: The humanized antivascular endothelial growth factor (VEGF) antibody bevacizumab (Bev) is efficacious for the treatment of NF2-related schwannomatosis (NF2), previously known as neurofibromatosis type 2. This study evaluated the safety and efficacy of a VEGF receptor (VEGFR) vaccine containing VEGFR1 and VEGFR2 peptides in patients with NF2 with progressive schwannomas (jRCTs031180184). MATERIALS AND METHODS: VEGFR1 and VEGFR2 peptides were injected subcutaneously into infra-axillary and inguinal regions, once a week for 4 weeks and then once a month for 4 months. The primary end point was safety. Secondary end points included tolerability, hearing response, imaging response, and immunologic response. RESULTS: Sixteen patients with NF2 with progressive schwannomas completed treatment and were assessed. No severe vaccine-related adverse events occurred. Among the 13 patients with assessable hearing, word recognition score improved in five patients at 6 months and two at 12 months. Progression of average hearing level of pure tone was 0.168 dB/mo during the year of treatment period, whereas long-term progression was 0.364 dB/mo. Among all 16 patients, a partial response was observed in more than one schwannoma in four (including one in which Bev had not been effective), minor response in 5, and stable disease in 4. Both VEGFR1-specific and VEGFR2-specific cytotoxic T lymphocytes (CTLs) were induced in 11 patients. Two years after vaccination, a radiologic response was achieved in nine of 20 assessable schwannomas. CONCLUSION: This study demonstrated the safety and preliminary efficacy of VEGFR peptide vaccination in patients with NF2. Memory-induced CTLs after VEGFR vaccination may persistently suppress tumor progression.
- Open Access
- 18 June 2024
- Published by Wiley in Cancer Science
- Vol. 115 (9) , 2879-2892
Tumor eradication by triplet therapy with BRAF inhibitor, TLR 7 agonist, and PD‐1 antibody for BRAF‐mutated melanoma
Programmed death 1 (PD‐1)/programmed death‐ligand 1 inhibitors are commonly used to treat various cancers, including melanoma. However, their efficacy as monotherapy is limited, and combination immunotherapies are being explored to improve outcomes. In this study, we investigated a combination immunotherapy involving an anti‐PD‐1 antibody that blocks the major adaptive immune‐resistant mechanisms, a BRAF inhibitor that inhibits melanoma cell proliferation, and multiple primary immune‐resistant mechanisms, such as cancer cell‐derived immunosuppressive cytokines, and a Toll‐like receptor 7 agonist that enhances innate immune responses that promote antitumor T‐cell induction and functions. Using a xenogeneic nude mouse model implanted with human BRAF‐mutated melanoma, a BRAF inhibitor vemurafenib was found to restore T‐cell‐stimulatory activity in conventional dendritic cells by reducing immunosuppressive cytokines, including interleukin 6, produced by human melanoma. Additionally, intravenous administration of the Toll‐like receptor 7 agonist DSR6434 enhanced tumor growth inhibition by vemurafenib through stimulating the plasmacytoid dendritic cells/interferon‐α/natural killer cell pathways and augmenting the T‐cell‐stimulatory activity of conventional dendritic cells. In a syngeneic mouse model implanted with murine BRAF‐mutated melanoma, the vemurafenib and DSR6434 combination synergistically augmented the induction of melanoma antigen gp100‐specific T cells and inhibited tumor growth. Notably, only triplet therapy with vemurafenib, DSR6434, and the anti‐PD‐1 antibody resulted in complete regression of SIY antigen‐transduced BRAF‐mutated melanoma in a CD8 T‐cell‐dependent manner. These findings indicate that a triple‐combination strategy targeting adaptive and primary resistant mechanisms while enhancing innate immune responses that promote tumor‐specific T cells may be crucial for effective tumor eradication.
- 18 June 2024
- Published by Wiley in Cancer Science
- Vol. 115 (9) , 2879-2892
Open AccessTumor eradication by triplet therapy with BRAF inhibitor, TLR 7 agonist, and PD‐1 antibody for BRAF‐mutated melanoma
Programmed death 1 (PD‐1)/programmed death‐ligand 1 inhibitors are commonly used to treat various cancers, including melanoma. However, their efficacy as monotherapy is limited, and combination immunotherapies are being explored to improve outcomes. In this study, we investigated a combination immunotherapy involving an anti‐PD‐1 antibody that blocks the major adaptive immune‐resistant mechanisms, a BRAF inhibitor that inhibits melanoma cell proliferation, and multiple primary immune‐resistant mechanisms, such as cancer cell‐derived immunosuppressive cytokines, and a Toll‐like receptor 7 agonist that enhances innate immune responses that promote antitumor T‐cell induction and functions. Using a xenogeneic nude mouse model implanted with human BRAF‐mutated melanoma, a BRAF inhibitor vemurafenib was found to restore T‐cell‐stimulatory activity in conventional dendritic cells by reducing immunosuppressive cytokines, including interleukin 6, produced by human melanoma. Additionally, intravenous administration of the Toll‐like receptor 7 agonist DSR6434 enhanced tumor growth inhibition by vemurafenib through stimulating the plasmacytoid dendritic cells/interferon‐α/natural killer cell pathways and augmenting the T‐cell‐stimulatory activity of conventional dendritic cells. In a syngeneic mouse model implanted with murine BRAF‐mutated melanoma, the vemurafenib and DSR6434 combination synergistically augmented the induction of melanoma antigen gp100‐specific T cells and inhibited tumor growth. Notably, only triplet therapy with vemurafenib, DSR6434, and the anti‐PD‐1 antibody resulted in complete regression of SIY antigen‐transduced BRAF‐mutated melanoma in a CD8 T‐cell‐dependent manner. These findings indicate that a triple‐combination strategy targeting adaptive and primary resistant mechanisms while enhancing innate immune responses that promote tumor‐specific T cells may be crucial for effective tumor eradication.